ArticleThe Journal of experimental medicine2018
Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses.
Open access · bronzeAbstract read
In one paragraph
Article in The Journal of experimental medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 355 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
355citing papers in PubMed, 2 pooled it
19.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
355 citing papers in PubMed, 2 syntheses or guidelines pooled it, 506 citations in OpenAlex.
- Takotsubo syndrome and vaccines: a systematic review.ESC heart failure · 2024Pooled it
- A systematic and thematic analysis of the top 100 cited articles on mRNA vaccine indexed in Scopus database.Human vaccines & immunotherapeutics · 2022Pooled it
- An mRNA-lipid nanoparticle vaccine targeting theMolecular therapy. Nucleic acids · 2026Article
- PEG-associated efficacy loss in lipid nanoparticles persists across formulation modifications for mRNA delivery.Drug delivery and translational research · 2026Article
- Bioengineering strategies for improving the immunogenicity of mRNA vaccines.Signal transduction and targeted therapy · 2026Review
- Development of an mRNA vaccine against the OprF ofMicrobiology spectrum · 2026Article
- Article
- An In Vitro Screen Identifies H1 Influenza Hemagglutinin Substitutions That Alter mRNA-LNP Vaccine Responses Against the Stalk Domain.Vaccines · 2026Article
- Article
- Bacterial mRNA Vaccines: Programming Immunity Against Antimicrobial Resistance.Drug development research · 2026Review
- mRNA-based influenza vaccine expands the B cell response breadth in humans.Nature immunology · 2026Observational
- SORT LNPs encapsulating Cas9 mRNA achieve efficient editing in skeletal muscle in a dystrophic mouse model.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- The impact of psuedouridine modification on human tRNA.Biochemical Society transactions · 2026Review
- Suppressor tRNA-mediated conditionally replicating live vaccine effectively protects pigs against Seneca Valley virus challenge.NPJ vaccines · 2026Article
- Programming the immunological properties of mRNA vaccines for cancer.Nature reviews. Immunology · 2026Review
- A bivalent mRNA-LNP vaccine confers broad-spectrum protection against both homologous and heterologous H5/H7 highly pathogenic avian influenza viruses in SPF chickens.Veterinary research · 2026Article
- Perturbation of RNA homeostasis impairs mitochondrial respiration during poxvirus infection through excess RNA accumulation.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- mRNA vaccines engage unconventional pathways in CD8Nature · 2026Article
- Review
- Transdermal Delivery of an mRNA-Liposome Vaccine via Dissolving Microneedle to Preserve Vaccine Activity and Enhance Immune Activation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
295 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors at 10 institutions in 3 countries.
Norbert PardiDepartment of Medicine, University of Pennsylvania, Philadelphia, PA pnorbert@pennmedicine.upenn.edu.ORCID 0000-0003-1008-6242
Michael J HoganDepartment of Medicine, University of Pennsylvania, Philadelphia, PA.
Martin S NaradikianDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Kaela ParkhouseDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0001-7608-4464
Derek W CainDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC.
Letitia JonesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC.ORCID 0000-0002-1889-5629
M Anthony MoodyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC.ORCID 0000-0002-3890-5855
Hans P VerkerkeDepartment of Medicinal Chemistry, University of Washington, Seattle, WA.
Arpita MylesDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Elinor WillisDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Celia C LaBrancheDepartment of Surgery, Duke University Medical Center, Durham, NC.ORCID 0000-0002-6653-6655
David C MontefioriDepartment of Surgery, Duke University Medical Center, Durham, NC.
Jenna L LobbyDepartment of Pathology, The Children's Hospital of Philadelphia, Philadelphia, PA.
Kevin O SaundersDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC.
Hua-Xin LiaoDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC.ORCID 0000-0002-7871-1334
Bette T KorberLos Alamos National Laboratory, Los Alamos, NM.ORCID 0000-0002-2026-5757
Laura L SutherlandDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC.ORCID 0000-0003-4119-3884
Richard M ScearceDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC.ORCID 0000-0002-6361-3758
Peter T HraberLos Alamos National Laboratory, Los Alamos, NM.ORCID 0000-0002-2920-4897
István TombáczDepartment of Medicine, University of Pennsylvania, Philadelphia, PA.
Hiromi MuramatsuDepartment of Medicine, University of Pennsylvania, Philadelphia, PA.
Houping NiDepartment of Medicine, University of Pennsylvania, Philadelphia, PA.
Daniel A BalikovDepartment of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0003-0392-5087
Charles LiDepartment of Medicine, University of Pennsylvania, Philadelphia, PA.
Barbara L MuiAcuitas Therapeutics, Vancouver, BC, Canada.
Ying K TamAcuitas Therapeutics, Vancouver, BC, Canada.
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0003-4121-776X
Katalin KarikóBioNTech RNA Pharmaceuticals, Mainz, Germany.ORCID 0000-0002-1864-3851
Patricia PolacinoWashington National Primate Research Center, University of Washington, Seattle, WA.
Laurence C EisenlohrDepartment of Pathology, The Children's Hospital of Philadelphia, Philadelphia, PA.
Thomas D MaddenAcuitas Therapeutics, Vancouver, BC, Canada.
Michael J HopeAcuitas Therapeutics, Vancouver, BC, Canada.
Mark G LewisBioqual Inc., Rockville, MD.
Kelly K LeeDepartment of Medicinal Chemistry, University of Washington, Seattle, WA.
Shiu-Lok HuWashington National Primate Research Center, University of Washington, Seattle, WA.
Scott E HensleyDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Michael P CancroDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Barton F HaynesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC.ORCID 0000-0002-7643-9023
Drew WeissmanDepartment of Medicine, University of Pennsylvania, Philadelphia, PA dreww@pennmedicine.upenn.edu.ORCID 0000-0002-1501-6510
University of Pennsylvania · USDuke University · USAcuitas Therapeutics (Canada) · CAUniversity of Washington · USChildren's Hospital of Philadelphia · USDuke Medical Center · USLos Alamos National Laboratory · USBioNTech (Germany) · DEBioqual · USIcahn School of Medicine at Mount Sinai · US
Funding
Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI MCMICHAEL, ANDREW JAMES · 2012 to 2018
$204.7MVirus and Antibody Gene Sequencing CoreP01AI131251 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Kevin Wiehe · 2017 to 2026
$40.7MRuth L. Kirschstein National Research Service Award (NRSA)- T32T32AI007392 · NIAID · DUKE UNIVERSITY · PI Amy Lynn Corneli, Guido Ferrari · 1990 to 2026
$9.8MUnderstanding Human B Cell Responses to Influenza to Improve the Influenza U19AI109946 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI RAVETCH, JEFFREY VICTOR · 2014 to 2018
$9.6MImmune System Development and RegulationT32AI055428 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ALLMAN, DAVID M, OLIVER, PAULA MARIA · 2003 to 2025
$4.2MImpact of prior influenza exposures on antibody repertoires to new viral strainsR01AI108686 · NIAID · WISTAR INSTITUTE · PI HENSLEY, SCOTT ERIC · 2014 to 2022
$3.7MRNA DELIVERY FOR DENDRITIC CELL HIV ANTIGEN PREVENTIONR01AI050484 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI WEISSMAN, DREW · 2002 to 2011
$3.6MWaters ACQUITY UPLC M-Class with NanoLockSpray ionization sourceR01GM099989 · NIGMS · UNIVERSITY OF WASHINGTON · PI LEE, KELLY KEISEN · 2012 to 2020
$3.5MVMD-PhD Training in Infectious Disease-Related ResearchT32AI070077 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Michael Lee Atchison · 2008 to 2026
$3.5MNucleoside modified mRNA based HIV vaccineR01AI124429 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI WEISSMAN, DREW · 2016 to 2019
$3.4MMechanistic studies of BLyS-mediated modulation in HIV-1 Env-specific antibody responsesR01AI118691 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI CANCRO, MICHAEL PAUL · 2015 to 2019
$3.4MThe effect of human pre-exposure history on antigenic drift of influenza virusesR01AI113047 · NIAID · WISTAR INSTITUTE · PI HENSLEY, SCOTT ERIC · 2014 to 2018
$2.5MNIAID NIH HHS P01 AI131251NIAID NIH HHS R01 AI041860NIAID NIH HHS R01 AI050484NIAID NIH HHS R01 AI108686NIAID NIH HHS R01 AI113047NIAID NIH HHS R01 AI118691NIAID NIH HHS R01 AI124429NIAID NIH HHS T32 AI007392NIAID NIH HHS T32 AI055428NIAID NIH HHS T32 AI070077NIAID NIH HHS U19 AI109946NIAID NIH HHS UM1 AI100645NIGMS NIH HHS R01 GM099989
Abstract
T follicular helper (Tfh) cells are required to develop germinal center (GC) responses and drive immunoglobulin class switch, affinity maturation, and long-term B cell memory. In this study, we characterize a recently developed vaccine platform, nucleoside-modified, purified mRNA encapsulated in lipid nanoparticles (mRNA-LNPs), that induces high levels of Tfh and GC B cells. Intradermal vaccination with nucleoside-modified mRNA-LNPs encoding various viral surface antigens elicited polyfunctional, antigen-specific, CD4
Indexed as
Adjuvants, ImmunologicAnimalsAntibodies, NeutralizingAntibody FormationAntigensB-LymphocytesGerminal CenterLipidsMacaca mulattaNanoparticlesNucleosidesProtein SubunitsRNA, MessengerTime FactorsT-Lymphocytes, Helper-InducerVaccinationAdjuvants, ImmunologicAntibodies, NeutralizingAntigensLipidsNucleosidesProtein SubunitsRNA, MessengerVaccines, Subunit
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.